Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipocine Inc LPCN

Healthcare Biotechnology
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor... see more

Recent & Breaking News (NDAQ:LPCN)

Lipocine Announces Successful Phase 1 Results With LPCN 1107, Potentially the First Oral Product for the Prevention of Preterm Birth

GlobeNewswire May 15, 2014

Lipocine Announces Financial and Operational Results for the First Quarter of 2014

GlobeNewswire May 13, 2014

Lipocine Announces Completion of Enrollment in its SOAR Phase 3 Study for Oral Testosterone Replacement Therapy

GlobeNewswire April 29, 2014

Lipocine to Begin Trading on the NASDAQ Capital Market

GlobeNewswire March 18, 2014

Lipocine to Present at the 26th Annual ROTH Conference

GlobeNewswire March 5, 2014

Lipocine Announces First Patient Dosed in Phase 3 Study for Oral Testosterone Replacement Therapy

GlobeNewswire February 10, 2014

Lipocine to Present at the 2014 Leerink Global Healthcare Conference

Globe Newswire February 4, 2014

Lipocine Announces New Appointments to Its Board of Directors

Globe Newswire January 7, 2014

Lipocine Chairman Receives Honorary Doctor of Science Degree From the University of Michigan

Globe Newswire December 13, 2013

Lipocine Inc. Announces Exercise and Closing of Over-Allotment Option

Globe Newswire December 6, 2013

Lipocine Inc. Announces Pricing of Public Offering of Common Stock

Globe Newswire November 27, 2013

Lipocine Inc. Appoints Morgan Brown as Executive Vice President and Chief Financial Officer

Business Wire September 16, 2013

Lipocine Inc. Announces Change in Trading Symbol

Business Wire August 22, 2013

Lipocine Inc. Announces Closing of $38 Million Private Placement to Advance Its Oral Testosterone Product Portfolio

Business Wire July 31, 2013

Lipocine Inc. Announces Reverse Merger and $38 Million Private Placement to Advance its Oral Testosterone Product Portfolio

Business Wire July 26, 2013